Kinase insert domain receptor. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Lenvatinib CHEMBL1289601 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 209 |
| Anlotinib CHEMBL4303201 |
Vascular endothelial growth factor receptor 2 inhibitor Inhibitor Small molecule |
✓ Both | 76 |
| Fruquintinib CHEMBL4303214 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 51 |
| Cabozantinib CHEMBL2105717 |
Vascular endothelial growth factor receptor 2 inhibitor Inhibitor Small molecule |
✓ Both | 48 |
| Regorafenib CHEMBL1946170 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 43 |
| Ramucirumab CHEMBL1743062 |
Vascular endothelial growth factor receptor 2 inhibitor Inhibitor Antibody |
✓ Both | 30 |
| Surufatinib CHEMBL4297190 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 25 |
| Axitinib CHEMBL1289926 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 24 |
| Sunitinib CHEMBL535 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Vascular endothelial growth factor receptor 2 inhibitor Inhibitor Small molecule |
✓ Both | 21 |
| Sorafenib CHEMBL1336 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 15 |
| Famitinib CHEMBL1278146 |
Vascular endothelial growth factor receptor 2 inhibitor Inhibitor Small molecule |
✓ Both | 11 |
| Cabozantinib S-malate CHEMBL2103868 |
Vascular endothelial growth factor receptor 2 inhibitor Inhibitor Small molecule |
ChEMBL only | 10 |
| Cediranib Maleate CHEMBL2103798 |
Inhibits KDR Primary target Small molecule |
Guide to Pharmacology only | 10 |
| Pazopanib CHEMBL477772 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 10 |
| Rivoceranib CHEMBL3186534 |
Vascular endothelial growth factor receptor 2 inhibitor Inhibitor Small molecule |
✓ Both | 9 |
| Nintedanib CHEMBL502835 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 7 |
| Midostaurin CHEMBL608533 |
Vascular endothelial growth factor receptor 2 inhibitor Inhibitor Small molecule |
ChEMBL only | 5 |
| Chiauranib CHEMBL5095033 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 3 |
| Sunitinib Malate CHEMBL1567 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 3 |
| Vandetanib CHEMBL24828 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 3 |
| Tivozanib CHEMBL1289494 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Non-small cell lung carcinoma | 12 | Phase 3 |
| Colorectal cancer | 10 | Phase 3 |
| Breast cancer | 9 | Phase 3 |
| Hepatocellular carcinoma | 9 | Phase 3 |
| Acute myeloid leukemia | 7 | Phase 3 |
| Fallopian tube cancer | 7 | Phase 3 |
| Primary peritoneal carcinoma | 6 | Phase 3 |
| Renal cell adenocarcinoma | 6 | Phase 3 |
| Glioblastoma | 6 | Phase 2/3 |
| Age-related macular degeneration | 5 | Phase 3 |
| Cancer | 5 | Phase 3 |
| Clear cell renal carcinoma | 5 | Phase 3 |
| Differentiated thyroid carcinoma | 5 | Phase 3 |
| Endometrial cancer | 5 | Phase 3 |
| Esophageal squamous cell carcinoma | 5 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
